Vascepa's List Price and Discounts
Vascepa (icosapent ethyl), used to lower triglycerides and reduce cardiovascular risk, has a wholesale acquisition cost (WAC) of about $320–$350 for a 30-day supply of 4 capsules (1 gram each, taken twice daily). Patient out-of-pocket costs often drop to $25–$50 per month with coupons from sites like GoodRx or manufacturer savings cards from Amarin, which cap copays at $9 for eligible commercially insured patients.[1][2]
How Vascepa Compares to Lovaza (Prescription Omega-3)
Lovaza, another prescription fish oil (omega-3 acid ethyl esters), costs $250–$300 for a comparable 30-day supply (4 grams daily). Vascepa is 10–30% more expensive at list price but purified to contain only EPA, unlike Lovaza's EPA/DHA mix. With discounts, both hover around $20–$40 monthly for insured patients. Vascepa's edge comes from stronger outcome data (e.g., REDUCE-IT trial), justifying the premium for high-risk patients.[1][3]
Vascepa vs. Generic Icosapent Ethyl
Since generic icosapent ethyl launched in 2020 after patent settlements, prices fell sharply. Generic versions cost $20–$50 per month—up to 85% less than branded Vascepa. Hikma and Dr. Reddy's generics dominate, with GoodRx prices as low as $15 for 120 capsules. Branded Vascepa remains pricier due to marketing and copay assistance, but generics are now the default for cost-conscious prescribers.[2][4]
Comparison to Statins and Other CV Meds
Vascepa adds $3,800–$4,200 annually at list price on top of statins like atorvastatin (generic: $5–$15/month). It's far costlier than fenofibrate generics ($10–$30/month) for triglycerides, but payers favor it over statins alone for CV event reduction in trials. Compared to newer options like Nexletol (bempedoic acid, $300+/month), Vascepa generics are cheaper.[1][5]
| Medication | Monthly List Cost (4g equiv.) | Generic Monthly Cost | Common Use |
|------------|-------------------------------|----------------------|------------|
| Vascepa (brand) | $320–$350 | N/A | CV risk + triglycerides |
| Generic icosapent ethyl | N/A | $20–$50 | Same |
| Lovaza | $250–$300 | $50–$100 | Triglycerides |
| Atorvastatin (generic) | N/A | $5–$15 | Cholesterol/CV risk |
| Fenofibrate (generic) | N/A | $10–$30 | Triglycerides |
Insurance Coverage and Real-World Costs
Most commercial plans cover Vascepa (80–90% tier 2/3), but step therapy often requires failing statins/fibrates first. Medicare Part D averages $100–$200/month without assistance. Biosimilar threats are minimal as it's synthetic, not biologic. Patent expirations (e.g., key method-of-use patents challenged) keep generic pressure high—no major exclusivity left post-2020.[4][6]
Factors Driving Cost Differences
Vascepa's price reflects FDA-approved CV outcomes data absent in OTC fish oils ($10–$20/month, unproven for events). Generic entry slashed costs, but branded use persists for patient assistance. Payers scrutinize it amid high U.S. spending ($1B+ peak sales).[3][5]
Sources:
[1] GoodRx.com - Vascepa Pricing
[2] Drugs.com - Vascepa Coupons
[3] DrugPatentWatch.com - Vascepa Patents & Generics
[4] FDA Orange Book - Icosapent Ethyl Approvals
[5] IQVIA Data via FiercePharma - Omega-3 Market
[6] Amarin Investor Reports - Generic Impact